1. Home
  2. STEX vs SERA Comparison

STEX vs SERA Comparison

Compare STEX & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STEX

Streamex Corp.

N/A

Current Price

$2.05

Market Cap

297.8M

Sector

N/A

ML Signal

N/A

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

HOLD

Current Price

$2.13

Market Cap

107.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEX
SERA
Founded
2009
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
297.8M
107.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
STEX
SERA
Price
$2.05
$2.13
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
2.4M
23.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.66
EPS
N/A
N/A
Revenue
N/A
$77,000.00
Revenue This Year
N/A
$25.84
Revenue Next Year
N/A
$715.79
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$1.37
52 Week High
$7.44
$4.35

Technical Indicators

Market Signals
Indicator
STEX
SERA
Relative Strength Index (RSI) 32.43 27.11
Support Level N/A $1.37
Resistance Level $3.68 $3.45
Average True Range (ATR) 0.26 0.21
MACD -0.01 -0.01
Stochastic Oscillator 4.83 7.14

Price Performance

Historical Comparison
STEX
SERA

About STEX Streamex Corp.

Streamex Corp is a vertically integrated technology and infrastructure company. It is focused on the tokenization and digitalization of real-world assets. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: